BlossomHill Therapeutics (NASDAQ:BLSM) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of BlossomHill Therapeutics (NASDAQ:BLSM) from a sell rating to a hold rating in a research report report published on Saturday morning,Wall Street Zen reports.

A number of other analysts have also weighed in on the stock. HC Wainwright reiterated a “buy” rating on shares of BlossomHill Therapeutics in a research note on Wednesday, September 30th. Leerink Partners raised their target price on shares of BlossomHill Therapeutics from $36.00 to $40.00 and gave the stock an “outperform” rating in a report on Monday, September 21st. Guggenheim boosted their target price on shares of BlossomHill Therapeutics from $30.00 to $40.00 and gave the company a “buy” rating in a research report on Monday, September 21st. Lifesci Capital began coverage on shares of BlossomHill Therapeutics in a report on Tuesday, September 1st. They issued an “outperform” rating and a $32.00 price target on the stock. Finally, JPMorgan Chase & Co. started coverage on BlossomHill Therapeutics in a research report on Tuesday, September 1st. They set an “overweight” rating and a $28.00 price target on the stock. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $35.00.

BlossomHill Therapeutics Trading Up 12.0%

NASDAQ:BLSM opened at $16.39 on Friday. BlossomHill Therapeutics has a fifty-two week low of $12.93 and a fifty-two week high of $27.99. The firm has a 50-day moving average price of $19.04.

BlossomHill Therapeutics (NASDAQ:BLSM) last announced its earnings results on Friday, September 18th. The company reported ($8.75) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($7.91). As a group, equities research analysts forecast that BlossomHill Therapeutics will post -5.54 EPS for the current year.

Insider Transactions at BlossomHill Therapeutics

In other BlossomHill Therapeutics news, General Counsel Vincent Liptak bought 2,500 shares of BlossomHill Therapeutics stock in a transaction dated Friday, August 7th. The stock was acquired at an average cost of $15.80 per share, for a total transaction of $39,500.00. Following the completion of the transaction, the general counsel directly owned 109,212 shares of the company’s stock, valued at approximately $1,725,549.60. This represents a 2.34% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Bihua Chen acquired 312,500 shares of the business’s stock in a transaction on Monday, August 10th. The stock was acquired at an average price of $16.00 per share, with a total value of $5,000,000.00. Following the acquisition, the director owned 3,614,034 shares in the company, valued at $57,824,544. The trade was a 9.47% increase in their position. The SEC filing for this purchase provides additional information. Insiders acquired 1,573,900 shares of company stock worth $25,181,900 in the last quarter.

BlossomHill Therapeutics Company Profile

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.